Posts by: Jose Marques Lopes, PhD

News

Treatment with the investigational vaccine IFN-alpha Kinoid increased the number of systemic lupus erythematosus (SLE) patients achieving low disease activity, lessened their use of corticosteroids, and was well-tolerated, according to ... Read more

February 1, 2019

Osteopontin Levels Linked to Poor Kidney Function, Higher Disease Activity in SLE Patients, Study Reports

News

In patients with recent-onset systemic lupus erythematosus (SLE), higher levels of a protein called osteopontin seem to be associated with lupus nephritis and more disease activity, but not with the ... Read more

January 18, 2019

Rubella Immunity Lowers Over Time in Vaccinated Adolescents with Lupus, Study Finds

News

Vaccinated patients with highly active systemic lupus erythematosus seem to lose their immunity levels over time, a study in rubella-vaccinated adolescents suggests. The study, “Risk factors associated with accelerated rubella-IgG antibody ... Read more

January 11, 2019

Neovacs, Centurion Pharma Continue Joint Development of SLE Vaccine IFNalpha Kinoid

News

Neovacs and Centurion Pharma will continue the joint development of the investigational vaccine IFNalpha Kinoid for people with systemic lupus erythematosus (SLE) based on the positive results of a ... Read more

January 2, 2019

Low-dose Add-on Voclosporin Increases Renal Remission in Lupus Nephritis Patients, Phase 2 Trial Shows

News

The addition of low-dose voclosporin to standard therapy led to significantly greater remission but a higher incidence of adverse events in systemic lupus erythematosus (SLE) patients with active lupus ... Read more

December 14, 2018

Urinary G3BP Protein Levels Could Be Biomarker for Lupus Nephritis Activity, Study Finds

News

The levels of galectin-3 binding protein (G3BP) in urine could be used as a biomarker of renal disease activity for systemic lupus erythematosus (SLE) patients with lupus nephritis, according ... Read more

December 10, 2018December 10, 2018

Low-dose Leflunomide Effective Induction Therapy for Lupus Nephritis, Phase 2/3 Trial Finds

News

A low dose of the immunosuppressant leflunomide is as safe and effective as the standard of care cyclophosphamide for induction treatment of patients with lupus nephritis, according to a Phase 2/3 trial ... Read more

December 5, 2018

Evobrutinib’s Effects on Macrophages Could Be Beneficial for SLE Treatment, Study Suggests

News

The investigational compound evobrutinib acts on the immune system by promoting anti-inflammatory behavior of macrophages — immune cells that engulf and digest pathogens — and the death of pro-inflammatory ... Read more

November 30, 2018

Hydroxychloroquine Use Lowers Risk for Atrial Fibrillation in SLE Patients, Study Reports

News

Systemic lupus erythematosus (SLE) patients using hydroxychloroquine have a markedly lower risk of a type of abnormal heart rhythm called atrial fibrillation than those not being treated with the therapy, ... Read more

This is a short description about myself and what this site is about. I hope you enjoy being here!

Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

Vaccine, IFNalpha Kinoid, Seen to Lower Disease Activity and Steroid Use in Phase 2b Trial

Osteopontin Levels Linked to Poor Kidney Function, Higher Disease Activity in SLE Patients, Study Reports

Rubella Immunity Lowers Over Time in Vaccinated Adolescents with Lupus, Study Finds

Neovacs, Centurion Pharma Continue Joint Development of SLE Vaccine IFNalpha Kinoid

Top 10 Lupus Stories of 2018

Low-dose Add-on Voclosporin Increases Renal Remission in Lupus Nephritis Patients, Phase 2 Trial Shows

Urinary G3BP Protein Levels Could Be Biomarker for Lupus Nephritis Activity, Study Finds

Low-dose Leflunomide Effective Induction Therapy for Lupus Nephritis, Phase 2/3 Trial Finds

Evobrutinib’s Effects on Macrophages Could Be Beneficial for SLE Treatment, Study Suggests

Hydroxychloroquine Use Lowers Risk for Atrial Fibrillation in SLE Patients, Study Reports

Pin It on Pinterest